Menu
Developed in Response to the Need for Change
GoodCap Pharmaceuticals, co-founded by molecular biologist Dr. Darryl Hudson and innovative entrepreneur Steven Sadoff, is dedicated to accelerating the recovery process for individuals struggling with mental health disorders.
Lead Candidate
GoodCap’s lead drug candidate, GCAP001, combines eugenol and psilocybin to better combat PTSD symptoms by targeting a broad array of physical markers
© 2023 All Rights Reserved
All trademarks are owned by GoodCap Pharmaceuticals or by third parties and may not be used without permission.
20+ years experience as CFO specializing in healthcare
Experienced public company board leader, audit committee chair, and is highly skilled in corporate governance including board refreshment, strategic alternatives and M&A for growth and highly regulated companies
Loyola University in MD (MBA) and Towson University (BS Business), is a Board Leadership Fellow (NACD) and a Certified Public Accountant (active status)
Deep expertise in molecular biology, neuroscience and genetics in psychedelics
Prior to founding GoodCap, Darryl co-founded InPlanta Biotechnology Inc. and Pathways Rx, where he led the development and commercialization of proprietary plant genetics
PhD in molecular biology and genetics from the University of Guelph
30+ years executive leadership in pharmaceutical R&D, manufacturing and operations
Sandoz, Novartis, Merck, Elan, Fougera, Cambrex
Led the commercialization of over 50 products covering a number of dosage forms, including Veregen, the first ever botanical drug approved by the FDA
Ph.D., Chemical Engineering, from the University of Delaware
Bachelor of Science, Chemical Engineering, from the New Jersey Institute of Technology
17+ years in the Pharma/Biotech sector as a Chief Financial Officer with extensive start-up, strategic, financial and operational experience
Was the COO & CFO of Cynapsus Therapeutics, a specialty CNS pharmaceutical company that developed Kynmobi®, a sublingual thin film strip for the treatment of OFF episodes associated with Parkinson’s disease
In October 2016, Cynapsus was acquired for $841 million by Sunovion Pharmaceuticals
While serving as CFO, Cynapsus raised approximately $170 million via private and public offerings, including $90 million from the proceeds of a US Initial Public Offering and NASDAQ listing.
BAH Economics from Queen’s University and MBA from Ivey School of Business at Western University
35+ years senior executive and board experience in Pharma/healthcare
Fmr. President/CEO Pharma Plus Drugmarts, Revlon Canada, TLC Laser Eye Centers and TouchLogic Corporation
Chair of Cynapsus Therapeutics which was acquired for $841million
Fmr. Director & Vice Chair of the Humber River Hospital
BScPhm, Pharmacy, University of Toronto
20+ years experience as leader in global drug development and commercialization
Experience across multiple therapeutic areas including Endocrine Disorders, Anti-infectives, Antivirals, Central Nervous System Disorders (Schizophrenia, Bipolar Disorders, Generalized Anxiety Disorders, Major Depression, Migraine, Anesthesia), Women’s Health, as well as a number of orphan indications
Board Director in private and public-sector companies
Doctor of Philosophy (Ph.D.), Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey
More than 30 years as a serial entrepreneur and former venture capitalist
Broad experience pharmaceuticals, biologicals and vaccines in oncology and infectious diseases
Experienced in drug development, manufacturing, regulatory affairs (FDA, EMA, NICE, Health Canada, WHO and BfArM)
Held senior technical and international marketing positions with Pharmacia Canada Inc. (now Pfizer) and Connaught Laboratories Inc (now Sanofi-Pasteur Vaccines)
PhD in Medical Sciences from McMaster University
Serial entrepreneur at the lead of emerging industries
Co-founder of Cynapsus Therapeutics which was acquired for $841 million
Co-founded and is the former chairman of PharmaCan (later known as Cronos), which achieved a peak market capitalization of $7 billion
Co-founder of the Tokyo Smoke brand which is now owned by Canopy Growth after a purchase in 2018 for $542 million
Daniels Faculty of Architecture, Landscape, and Design at the University of Toronto
Professor in the Department of Symptom Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas
A pioneer in establishing the connection between depression and inflammation
Current research aims at understanding the role of inflammation and mitochondrial dysfunction in the pathophysiology of depression and fatigue
Authored more than 550 original research papers, reviews and book chapters on stress, anxiety, neuropeptides, brain-immune interactions, and inflammation-associated depression
Chair and professor with the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin
Co-director of the Center for Psychedelic Research and Therapy
Directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences
Former Chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine
Clinician Researcher in the Mount Sinai Hospital Inflammatory Bowel Disease Clinic. Director for the University of Toronto Division of Gastroenterology and Hepatology and a faculty member of the University of Toronto School of Public Health Institute for Health Policy, Management and Evaluation.
Founder of the Ontario Best Practices Research Initiative in IBD, Ontario’s premier source of real-world data and patient-reported data on IBD in Ontario. Authored or co-authored over 180 articles in peer-reviewed publications.
Current research focus on the costs and benefits of medications used in IBD, assessing how to optimize delivery of mental health care for persons with IBD in diverse practice settings.
Co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for mood disorders, PTSD, and substance use problems.
Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of psychedelic-assisted Psychotherapy and has served as a therapist on earlier FDA approved clinical trials of psilocybin-assisted treatments for treatment resistant depression.
Assistant Professor of Clinical Medical Psychology in Psychiatry and Project Clinician at Columbia University where her research includes qualitative and mixed-methods projects to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy.
Professor of Medicine at the University of Toronto, where he is a member of the Institute of Medical Science and secondarily appointed to the Department of Immunology
Gastroenterologist and internist at Mount Sinai Hospital in Toronto, Canada with 35+ years of experience in medical practice, teaching, and research focused on gut inflammation
Worked extensively with the Crohn’s and Colitis Foundation of Canada where he helped to develop the IBD Research Institute, and is now a project leader of the GEM Project, a global clinical study coordinated out of the IBD research group at the Zane Cohen Centre at Mount Sinai Hospital
Head of Interventional Psychiatry at UC San Diego, focusing on the development of novel treatments, including psychedelic medicines, for patients with severe mental illness
Highly active in the field of psychedelic science, where he has published on psychedelic microdosing and led several studies investigating the potential use of psychedelics for suicidality
Former clinical and research fellow in brain stimulation at the University of Toronto
15+ years of leadership experience across highly regulated industries with 100+ innovative product launches
Proven track record of growing sales, building brands, and leading product-development teams for Bacardi, Labatt, Novartis, and Jamieson Laboratories